These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18398974)

  • 1. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations.
    Raffa JD; Tossonian HK; Grebely J; Petkau AJ; DeVlaming S; Conway B
    J Acquir Immune Defic Syndr; 2008 Mar; 47(3):397-9. PubMed ID: 18398974
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired CD4+ cell recovery during antiretroviral therapy in patients with HIV resistance mutations.
    Sühs KW; Stoll M; Diem R; Schmidt RE; Heiken H
    Arch Virol; 2012 Mar; 157(3):433-40. PubMed ID: 22179846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors.
    Liu H; Miller LG; Hays RD; Golin CE; Wu T; Wenger NS; Kaplan AH
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):315-22. PubMed ID: 16540932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).
    Cingolani A; Antinori A; Rizzo MG; Murri R; Ammassari A; Baldini F; Di Giambenedetto S; Cauda R; De Luca A
    AIDS; 2002 Feb; 16(3):369-79. PubMed ID: 11834948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.
    Antinori A; Liuzzi G; Cingolani A; Bertoli A; Di Giambenedetto S; Trotta MP; Rizzo MG; Girardi E; De Luca A; Perno CF
    AIDS; 2001 Nov; 15(17):2325-7. PubMed ID: 11698709
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.
    Al Mazari A; Zomaya AY; Charleston M; Salem H; Maher A; Garsia RJ
    Curr HIV Res; 2007 Jul; 5(4):430-9. PubMed ID: 17627506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dearth of groundbreaking data at 14th international conclave of HIV medical community.
    MacDougall DS
    IAPAC Mon; 2002 Oct; 8(10):276-82. PubMed ID: 12510660
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunologic and virologic responses to antiretroviral therapy in treatment-naïve, HIV-infected elderly patients.
    Ocheretyaner ER; Yusuff J; Park TE
    Int J STD AIDS; 2019 Nov; 30(13):1304-1310. PubMed ID: 31726933
    [No Abstract]   [Full Text] [Related]  

  • 18. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective drug taking during combination antiretroviral therapy.
    Lanzafame M; Melotti R; Lattuada E; Boccafoglio F; Concia E; Verlato G; Vento S
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):490-1. PubMed ID: 17353720
    [No Abstract]   [Full Text] [Related]  

  • 20. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.